

# Chargeurs Buy

#### Equity Research from Kepler Cheuvreux

Release date: 22 February 2022

#### Baptiste de Leudeville

MCap: EUR498.3m

EV. 1 - 24 /42 /EUD)

Equity Research Analyst +33 1 53 65 36 55 bdeleudeville@keplercheuvreux.com

#### France | Support services

Target Price: EUR30.00 Current Price: EUR21.34 Up/downside: 40.6% Market data: 21 February 2022 Change in TP: none Change in Sales: **Change in Adj. EBIT:** -10.2% 21E/-0.8% 22E Change in Adj. EPS:

2.5% 21F/0.7% 22F -10.0% 21E/8.4% 22E

Bloomberg: CRI FP Reuters: CRIP.PA 53.9% Free float Avg. daily volume (EURm) 1.2 YTD abs performance -18.1% 52-week high/low (EUR) 28.94/20.72

# **Strong arguments for 2022**

## Why this report?

The outlook drawn by Chargeurs' management for 2022 suggests sustained growth and margin expansion (except CHS, against high comps) based on record order intake (CPF, PCC-CFT, and CMS), the embedded effect of price increases (CPF), operating leverage from greater volumes (CFT-PCC), and new synergies (CMS). Buy rating and EUR30 TP reiterated. The roll-out of the PAAS ("product as a service") model and an ambitious M&A programme make Chargeurs an attractive case.

### **Key findings**

- Sustained growth momentum maintained at CPF. Chargeurs manages to mitigate the inflation of input costs by using its pricing power.
- The acceleration of growth seen at CFT-CC since H2 2021 marks a shift in demand from the fashion sector. Higher volumes will drive sales and profit at the division in 2022.
- The museography platform is taking shape. The consolidation of the network opens up attractive commercial opportunities and cost synergy options.

#### **Deconstructing the forecasts**

■ We see 6% sales growth in 2022E and a slight increase in the adjusted EBIT margin (+30bps to 7.2%). Growth and margin expansion at traditional activities should more than offset the expected reduced contribution of CHS.

FY to 31/12 (EUR)	12/21E	12/22E	12/23E
Sales (m)	736.6	781.1	816.1
EBITDA adj (m)	73.8	80.1	88.7
EBIT adj (m)	50.7	56.3	64.7
Net profit adj (m)	30.6	34.3	41.3
Net financial debt (m)	146.0	134.5	119.1
FCF (m)	51.8	42.6	49.0
EPS adj. and ful. dil.	1.31	1.47	1.77
Consensus EPS	1.30	1.41	1.82
Net dividend	0.87	0.98	1.18
FY to 31/12	12/21E	12/22E	12/23E
P/E adj and ful. dil.	16.3	14.5	12.1
EV/EBITDA	9.2	8.4	7.4
EV/EBIT	13.4	11.9	10.1
EV/EBIT FCF yield	13.4 10.4%	11.9 8.5%	10.1 9.8%
'			
FCF yield	10.4%	8.5%	9.8%
FCF yield Dividend yield	10.4% 4.1%	8.5% 4.6%	9.8% 5.5%
FCF yield Dividend yield ND(F+IFRS16)/EBITDA	10.4% 4.1% 2.4	8.5% 4.6% 2.0	9.8% 5.5% 1.7
FCF yield Dividend yield ND(F+IFRS16)/EBITDA Gearing	10.4% 4.1% 2.4 61.7%	8.5% 4.6% 2.0 53.7%	9.8% 5.5% 1.7 44.3%

#### **Investment case**

- Chargeurs is an industrial conglomerate with world-leading positions in niche markets that are worth EUR0.5-1.0bn (e.g. self-adhesive films for surface protection, interlinings and technical textiles, premium wool trading).
- CEO and reference shareholder Michael Fribourg took over the company in 2015 and reshaped it. The group's portfolio of assets has been strengthened (higher share of services, innovative/sustainable products, more productive industrial facility) making Chargeurs a more diversified, performing and premium business.
- Chargeurs's premiumization and build-up strategy is expected to deliver double digit earnings growth in the next years.

#### **Catalysts**

- Recovery of retail-exposed businesses from depressed 2020
- Embedded performance of assets after a sustained investment period.
- Selective and stringent M&A strategy

#### Valuation methodology

- Discounted Cash Flow (7.9% WACC, 2% g).
- Sum-Of-The-Parts (applying various EV/EBITDA and EV/EBIT multiples to each division).

#### Risks to our rating

- High price of polyethylene pressuring margins at CPF.
- M&A execution (inadequate purchasing price, failure in the integration process)

Kepler Cheuvreux and the issuer have agreed that Kepler Cheuvreux will produce and disseminate investment research on the said issuer as a service to the issuer.

## 2021: solid performance overall

As anticipated, 2021 results marked a decline compared to 2020 (-10% in sales, -28% in EBITDA, -36% in adjusted EBIT, and -25% in net profit), given the very high comparison base resulting from the performance of CHS at the peak of the pandemic

Compared to 2019 (a more standard year for comparative analysis), Chargeurs posted double-digit growth in sales and EBIT (+18% and +23%) and doubled its net profit (from EUR15m to EUR31m).

The year was characterised by: 1) sustained demand at CPF; 2) a rebound of demand at CFT-PCC from the second half; and 3) the ramp-up of the museography platform at CMS.

The modest increase in the adjusted EBIT margin compared to 2019 (+30bps at 6.9%) is explained by a sharp increase in input costs, in particular at CPF, and the negative mix related to the significantly lower contribution of CHS.

Reported results are detailed in a table at the end of the report.

We also note:

- The acceleration of revenue growth in the fourth quarter (+43%), in particular at activities that have suffered most from the pandemic (CFT-PCC, CMS). This augurs well for the starting year.
- **Solid cash generation** of EUR65m, the second-highest figure in the group's recent history after the record EUR73m achieved in 2020, thanks to its financial performance and tight working capital management.
- Confirmation of the Leap Forward programme objectives, namely annual revenue of EUR1.5bn and recurring operating profit of EUR150m by 2025 (including M&A). This is to be achieved via: 1) the deployment of the PAAS (product as a service) model around co-innovation, digitalisation, traceability, and bespoke logistics in order to boost the value of assets and returns; and 2) value-accretive acquisitions.

### 2022 outlook

#### **Growth and margin expansion at traditional activities**

The outlook drawn by Chargeurs' management for 2022 suggests continued growth on the back of record order backlog at CPF, PCC-CFT, and CMS.

We see margin expansion at the same time, thanks to: 1) the embedded effect of price increases (CPF); 2) the operating leverage stemming from the expected increase in volumes (CFT-PCC); and 3) the synergies generated by the greater integration of newly-acquired entities (CMS).

#### **Further normalisation at CHS**

We expect the contribution of CHS to decrease again sharply in 2022 (2023 as well) with the end of health restrictions. Visibility remains low. We cut our revenue estimates for the division (EUR40m in 2022, and EUR30m in 2023 and beyond, compared to EUR50m previously).

#### 6% sales growth, 30bp increase in adjusted EBIT margin

By combining steady growth in sales/profit at traditional activities (CPF, CFT-PCC and CMS) and a lower contribution from CHS, we anticipate a 6% increase in sales and an 11% increase in EBIT at the group level (adjusted EBIT margin +30bps to 7.2%).

#### **Protective films (CPF)**

#### **Record annual sales**

2021 set a new record for CPF (EUR341m vs. c. EUR270-280m on average over 2017-20) with a 27% YOY increase in sales, driven by volume and price (+15% and +12, respectively). Growth remained at high levels in the fourth quarter (+24%), driven by sustained demand from key sectors (construction, appliances) and continuous price increases.

#### Resilience

Against a strong inflationary backdrop (the price of polyethylene surged by 90% between October 2020 and December 2021), CPF managed to improve margins. The EBITDA margin improved by 50bps (10.8%) and the current EBIT margin was up 140bps (7.7%). Profitability has benefited from higher volume and CPF's proven pricing power, as it is able to pass on a large part of the boom in polyethylene prices to customers, thanks to pass-through clauses. The further optimisation of production at the top-notch Italian coating line also contributed positively.

#### 2022 and beyond: room for sales growth and margin improvement

Despite a demanding comparison base, we see room for further growth heading towards 2022, based on: 1) further price increases being passed on in 2022; and 2) a record order backlog at the start of the year. The order backlog provides visibility up to "only" two months, but according to management, interactions with key clients indicate that demand could remain robust through 2022. Obviously, the development of the price of polyethylene will be a key factor to watch, since, if they normalise, prices will be on the decline at some point. In this scenario, CPF would benefit at the EBIT level, as there is traditionally a delay between the actual decrease in raw material prices and the corresponding adjustments in selling prices. We anticipate revenue growth of 6% YOY this year (EUR360m) and a 70bp improvement in the adjusted EBIT margin (7.7%).

#### **Trajectory to 2025**

Management reiterates its ambition for CPF of adjusted EBIT at EUR44m in 2025, suggesting a 14% CAGR, supported by dynamic market growth (5% a year structurally) and premiumisation (greater share of high-margin solvents and green solutions). This expected growth trajectory is purely organic-driven (likely no acquisitions to be made in this business). We believe Chargeurs has what it takes to achieve its plan (e.g. established global leadership, a unique range of products and services, top-notch manufacturing assets). Our 2025 estimates are aligned with management's targets.

#### **Fashion Technologies (CFT-PCC)**

#### Trend shift since H2 2021

The acceleration of top-line growth in the second half (+34% following stable sales in H1) highlights the steady recovery in the fashion and luxury sector since July, following a long period of inventory shedding. The last quarter was particularly strong (+48%), with revenues approaching Q4 2019 levels before the Covid crisis (EUR50m compared to EUR54m).

#### Unfavourable mix weighed on margins

The increase in activity did not result in higher profits, though (-100bp in adjusted EBIT margin), since CFT-PCC was penalised by a less favourable mix (lower volume provided to CHS for the manufacturing of masks, which resulted in the lower absorption of fixed costs).

### 2022: sales recovery to continue, margin driven by volume growth

The outlook for 2022 is positive thanks to a record order book at the start of 2022, as brands are accelerating their orders to support the recovery of demand. We expect business margins to benefit from higher volumes, despite a simultaneous increase in the cost base due to a persisting inflationary environment. With regards to the sales mix, the negative impact seen in H2 2021 could continue in H1 2022, considering that the mask business was strong in H1 2021 (EUR72m). The basis for comparison will ease afterwards. We model robust 30% revenue growth this year (EUR200m) along with 250bp upside to the adjusted EBIT margin (5.4%).

### PAAS model reflects in digitalisation and innovation

The PAAS ("product as a service") model at CFT-PCC is taking shape in digitalisation (customers have full digital access to all interlining ranges via the virtual showroom opened in July 2021, enabling them to digitally design their prototypes, with major benefits in terms of time to market and environmental footprint) and innovation as the Sustainable 360TM eco-responsible range is being extended with a view to targeting new market segments beyond the traditional luxury segment. Chargeurs mentions growing interest from a large number of affordable ready-to wear brands that are looking to increase the environmentally-responsible portion of their inputs.

#### **Trajectory to 2025**

Management confirms its adjusted EBIT target of EUR25m by 2025, from EUR5m in 2021 (KECH: EUR21m).

### **Healthcare Solutions (CHS)**

#### Finding its balance

2021 revenues of EUR95m were in the upper range of the guidance provided by the group at the start of the year (e.g. EUR50-100m). The business recorded a comfortable adjusted EBIT margin of 23%. Since the inception of the masks business in Q2 2020, we have seen a high degree of volatility in quarterly sales, which fluctuates according to the restocking operations made by clients.

In 2022, we expect most countries to end mask mandates in public spaces as health conditions improve globally. Therefore, a normalisation must be expected. That said, the wearing of masks will be significantly more widespread going forward than before the pandemic, even in the absence of government obligations. We sense that the revenue potential from selling masks in a post-pandemic world ranges from EUR20m to EUR50m at best. We model EUR40m in 2022 and EUR30m annually afterwards (vs. EUR50 per year previously).

At the same time, we set a higher adjusted EBIT of 21% going forward (16% previously) to reflect: 1) a very low cost structure; 2) a focus on value-added services (dynamic inventory management for key accounts, traceability, and recycling solutions); and 3) a focus on the premium travel retail sector.

#### Expected upside from M&A

At CHS, we assume that growth will come exclusively from potential acquisitions, as Chargeurs aims to diversify further into hygiene, beauty, and wellness products. The diversification has started with the acquisition of Fournival Altesse, a French leader in high-end brushes and a distribution partnership with Sockwell, a leading US brand in the compression sock sector. We expect more acquisitions going forward.

#### **Trajectory to 2025**

Management confirms an adjusted EBIT target of EUR15m by 2025, from EUR22m in 2021 (KECH: EUR6m).

### **Museum Solutions (CMS)**

### Integrated platform taking shape

The division posted solid sales growth in 2021 (+18% at EUR60m), of which half was achieved organically. We note the notable improvement of business profitability (8.3% vs. a 3.7% adjusted EBIT margin) and the revenue growth acceleration in the fourth quarter (+42%). Chargeurs is pursuing the integration of the companies acquired in the course of recent years (six in total) and the development of the museography platform, now organised around the Museum Studio umbrella brand. This way, Chargeurs pursues several goals, namely the creation of cost synergies (its UK-based subsidiaries now come under a single management and several support functions being pulled together), the strengthening of the brand image as a booster for business development, and a greater ability to attract the best talents in the industry.

#### **Building edges**

We continue to value Chargeurs' "one-stop shop" strategy in the field of services to museums, which we found very attractive. In a market that has remained highly fragmented to this date, as it is mostly composed of local/single-disciplinary players, CMS stands out for its ability to operate across the entire visitor experience value chain, including the planning, design, and production of large-scale museum projects, and across all regions (Europe, the US, the UK, Asia, the Middle East). The underlying market offers attractive prospects, driven by the multitude of new large-scale cultural projects around the world (Middle East, Asia, and the US in particular), the increasing sophistication of museums' offerings, and growing demand for living luxury experiences.

From EUR60m in revenue last year, we are looking at EUR81m/94m/103m in 2022/23/24 (+20/15/10% LFL, respectively). We factor in a EUR10m contribution in 2022 from Events



Communication. We anticipate margin expansion of 260bps over the next two years, driven by the materialisation of synergies and the accretive contribution of acquisitions.

### **Trajectory to 2025**

Management confirms the adjusted EBIT target of EUR18m by 2025 from EUR9m in 2021 (KECH: EUR18m).

#### Buy, EUR30 TP

We use a DCF and a sum-of-the-parts. We obtain a EUR30 TP by averaging the two methods.

The explicit period of our DCF expands over the period 2023-32. We use a WACC of 7.9% based on a beta of 1.20 and market premium of 8%. The long-term EBIT margin is set at 8.5% and terminal growth at 2%.

	1.00%	1.25%	1.50%	1.75%	2.00%	2.25%	2.50%	2.75%	3.00%
8.9%	26	27	27	28	29	29	30	31	32
8.7%	27	28	29	29	30	31	32	32	33
3.4%	29	29	30	31	31	32	33	34	35
3.2%	30	31	31	32	33	34	35	36	37
7.9%	31	32	33	34	35	36	37	38	39
7.7%	33	34	34	35	36	38	39	40	42
7.4%	34	35	36	37	38	40	41	43	45
7.2%	36	37	38	39	41	42	44	46	48
5.9%	38	39	40	42	43	45	47	49	51

We add a sum-of-the-parts to our valuation methods. We value each division using different multiples reflecting various strengths and weaknesses (growth and margin profile, market positioning, barriers to entry). The method derives a value of EUR25 per share, therefore providing less upside than the DCF.

Table 2: Sum-of-the-parts			
Business unit	EV	Weight	Multiples
Protective Films (CPF)	459	58%	10x EBITDA, 15x EBIT 2022E
Fashion Technologies (CFT)	133	17%	8x EBITDA, 12x EBIT 2022E
Luxury Materials (CLM)	14	2%	4x EBITDA, 6x EBIT 2022E
Museum Solutions (CMS)	121	15%	9x EBITDA, 13x EBIT 2022E
Healthcare Solutions (CHS)	58	7%	5x EBITDA, 8x EBIT 2022E
Eliminations	-82		11x EBIT
Enterprise Value	703		
Net debt	-117		
Equity value	586		
Per share (EUR)	25		
			Source: Kepler Cheuvreux

#### **Tables**

#### Reported results 2021 vs. 2020

			2020				2021				Change				
EURm	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
Protective Films (CPF)	71	63	67	70	270	77	92	86	86	341	8%	46%	28%	24%	26%
Fashion Technologies (CFT)	45	20	33	33	132	32	34	39	50	154	-30%	68%	19%	48%	17%
Luxury Materials (CLM)	30	10	10	14	65	18	21	22	25	86	-39%	104%	126%	72%	33%
Museum Solutions (CMS)	11	14	13	13	52	13	15	14	19	60	12%	8%	8%	40%	17%
Healthcare Solutions (CHS)	0	254	47	3	304	42	30	11	12	95	NA	-88%	-76%	307%	-69%
Group	158	361	170	134	822	181	192	173	191	737	15%	-47%	2%	43%	-10%
Group (excluding CHS)	158	107	123	131	518	139	162	162	179	642	-12%	51%	31%	37%	24%



	2020			2021			Change		
EURm	H1	H2	FY	H1	H2	FY	H1	H2	FY
Protective Films (CPF)	13	15	28	20	17	37	56%	12%	32%
Fashion Technologies (CFT)	5	6	11	6	5	11	12%	-17%	-4%
Luxury Materials (CLM)	-1	-1	-2	1	1	1	NA	NA	NA
Museum Solutions (CMS)	2	3	5	5	4	9	119%	46%	78%
Healthcare Solutions (CHS)	55	10	65	19	4	23	-67%	-59%	-65%
Others	-3	-1	-5	-3	-3	-6	NA	NA	NA
Group	71	31	102	46	28	74	-35%	-12%	-28%
Group (excluding CHS)	16	21	37	28	23	51	76%	10%	38%

Source: Kepler Cheuvreux

		2020			2021	
%	H1	H2	FY	H1	H2	FY
Protective Films (CPF)	9.5%	11.0%	10.3%	11.8%	9.8%	10.8%
Fashion Technologies (CFT)	7.9%	8.9%	8.4%	8.8%	5.5%	6.9%
Luxury Materials (CLM)	-2.2%	-5.4%	-3.4%	0.9%	1.3%	0.8%
Museum Solutions (CMS)	8.4%	10.5%	9.5%	16.8%	12.5%	14.4%
Healthcare Solutions (CHS)	21.8%	20.1%	21.5%	25.9%	17.4%	23.8%
Others	NA	NA	NA	NA	NA	NA
Group	13.7%	10.3%	12.5%	12.4%	7.6%	10.0%
Group (excluding CHS)	5.2%	8.4%	7.1%	9.2%	6.9%	8.0%

Source: Kepler Cheuvreux

		2020			2021			Change		
EURm	H1	H2	FY	H1	H2	FY	H1	H2	FY	
Protective Films (CPF)	7	10	17	14	12	26	104%	19%	54%	
Fashion Technologies (CFT)	2	3	5	2	2	5	0%	-21%	-12%	
Luxury Materials (CLM)	-1	-1	-2	1	1	1	-150%	-138%	-143%	
Museum Solutions (CMS)	1	1	2	3	2	5	238%	109%	163%	
Healthcare Solutions (CHS)	54	9	64	18	4	22	-67%	-61%	-66%	
Others	-4	-2	-6	-4	-4	-8	-3%	86%	29%	
Group	60	20	79	34	17	51	-43%	-16%	-36%	
Group (excluding CHS)	5	11	16	16	13	29	206%	24%	84%	

Source: Kepler Cheuvreux

		2020			2021	
%	H1	H2	FY	H1	H2	FY
Protective Films (CPF)	5.2%	7.4%	6.3%	8.4%	7.0%	7.7%
Fashion Technologies (CFT)	3.5%	4.2%	3.9%	3.5%	2.5%	2.9%
Luxury Materials (CLM)	-2.5%	-5.4%	-3.6%	1.3%	1.1%	1.2%
Museum Solutions (CMS)	3.2%	4.1%	3.7%	9.9%	7.0%	8.3%
Healthcare Solutions (CHS)	21.4%	18.5%	20.9%	25.4%	15.3%	22.9%
Others	NA	NA	NA	NA	NA	NA
Group	11.5%	6.5%	9.6%	9.1%	4.6%	6.9%
Group (excluding CHS)	2.0%	4.2%	3.0%	5.3%	3.8%	4.5%



	2020			2021		
EURm	H1	H2	FY	H1	H2	FY
Revenue	519	304	822	372	364	737
Growth	59%	1%	31%	-28%	20%	-10%
EBITDA	71	31	102	46	28	74
Growth	119%	14%	71%	-35%	-12%	-28%
EBITDA margin	13.7%	10.3%	12.5%	12.4%	7.6%	10.0%
EBIT, adj.	60	20	79	34	17	51
Growth	162%	6%	92%	-43%	-16%	-36%
EBIT margin	11.5%	6.5%	9.6%	9.1%	4.6%	6.9%
Net profit	29	11	40	25	6	31
Growth	248%	70%	169%	-15%	-46%	-24%
Net margin	5.6%	3.8%	4.9%	6.6%	1.7%	4.2%

# **Estimates (2022-24)**

EURm	2019	2020	2021	2022E	2023E	2024E
Revenues	278	270	341	360	370	382
Growth	-2%	-3%	26%	5%	3%	3%
EBITDA	33	28	37	43	48	52
EBITDA margin	11.9%	10.3%	10.8%	12.0%	13.0%	13.5%
EBIT, adj.	24	17	26	32	37	41
EBIT, adj. margin	8.5%	6.3%	7.7%	9.0%	10.1%	10.7%

Source: Kepler Cheuvreux

Table 10: Fashion Technologi	es (CFT)					
EURm	2019	2020	2021	2022E	2023E	2024E
Revenues	211	132	154	200	220	237
Growth	31%	-37%	17%	30%	10%	8%
EBITDA	24	11	11	17	21	25
EBITDA margin	11.4%	8.4%	6.9%	8.5%	9.5%	10.5%
EBIT, adj.	18	5	5	11	15	18
EBIT, adj. margin	8.3%	3.9%	2.9%	5.4%	6.7%	7.7%

Source: Kepler Cheuvreux

EURm	2019	2020	2021	2022E	2023E	2024E
Revenues	100	65	86	100	102	104
Growth	2%	-36%	33%	16%	3%	2%
EBITDA	3	-2	1	2	3	3
EBITDA margin	2.8%	-3.4%	1.4%	2.0%	3.0%	3.0%
EBIT, adj.	3	-2	1	2	3	3
EBIT, adj. margin	2.7%	-3.6%	1.2%	1.8%	2.8%	2.8%

Source: Kepler Cheuvreux

<b>Table 12: Museum Solutions</b>	(CMS)					
EURm	2019	2020	2021	2022E	2023E	2024E
Revenues	37	52	60	81	94	103
Growth	21%	38%	17%	35%	15%	10%
EBITDA	5	5	9	13	15	17
EBITDA margin	-11.8%	8.9%	14.4%	16.5%	16.5%	16.5%
EBIT, adj.	3	2	5	9	11	12
EBIT, adj. margin	7.5%	3.7%	8.3%	11.5%	11.8%	12.0%
					Course	Konlar Chamerous

Source: Kepler Cheuvreux



(CHS)					
2019	2020	2021	2022E	2023E	2024E
0	304	95	40	30	30
NA	NA	-65%	-58%	-25%	0%
0	65	23	10	7	7
NA	21.5%	23.8%	24.0%	24.0%	24.0%
0	64	22	9	6	6
NA	20.9%	22.9%	21.5%	20.7%	20.7%
	2019 0 NA 0 NA 0	2019 2020  0 304  NA NA  0 65  NA 21.5%  0 64	2019         2020         2021           0         304         95           NA         NA         -65%           0         65         23           NA         21.5%         23.8%           0         64         22	2019         2020         2021         2022E           0         304         95         40           NA         NA         -65%         -58%           0         65         23         10           NA         21.5%         23.8%         24.0%           0         64         22         9	2019         2020         2021         202E         203E           0         304         95         40         30           NA         NA         -65%         -58%         -25%           0         65         23         10         7           NA         21.5%         23.8%         24.0%         24.0%           0         64         22         9         6

Source: Kepler Cheuvreux

Table 14: Group						
EURm	2019	2020	2021	2022E	2023E	2024E
Revenues	626	822	737	781	816	855
Growth	9%	31%	-10%	6%	4%	5%
EBITDA	60	102	74	80	89	98
EBITDA margin	9.6%	12.5%	10.0%	10.3%	10.9%	11.4%
EBIT, adj.	41	79	51	56	65	73
EBIT, adj. margin	6.6%	9.6%	6.9%	7.2%	7.9%	8.5%



# **Company description**

Chargeurs is an industrial conglomerate that has established world-leading positions in niche markets (protective films, interlinings, premium wool trading, services to museums). In 2020, Chargeurs succesfully created Healthcare Solutions (CHS) to meet the booming demand for masks during the pandemic.

#### Management


Michaël Fribourg, CEO Olivier Buquen, CFO Gustave Gauquelin, COO


#### **Key shareholders**

Free float	53.90%
Colombus Holding SAS	27.10%
Sycomore Asset Management	8.70%
Amundi	5.70%

### **Key data charts**













### **SWOT** analysis

#### **Strengths**

- Dominating position in niche markets (EUR0.5-1.0bn market size)
- Differentiated offering (premium products, high quality services)
- Management (long term vision, entrepreneurial approach)
- Self-financing ability

#### Weaknesses

Sensitive to economic downturns (construction, apparel sector)

#### **Opportunities**

- Fast-growing museum services market
- Development of a platform around healthcare/beauty/hygiene/wellness
- M&A opportunities could arise as the crisis eases
- Growing demand for eco-friendly and sophisticated products

#### **Threats**

- Risks linked to the integration of newly-acquired companies
- Extension of the COVID-related restrictions and its impact
- Volatility of raw material price (polyester, polyamides)
- Intensification of the competitive landscape

Valuation table								Market data	as of: 21 Febr	ruary 2022
FY to 31/12 (EUR)	12/14	12/15	12/16	12/17	12/18	12/19	12/20	12/21E	12/22E	12/23E
Per share data (EUR)										
EPS adjusted		0.79	1.09	1.09	1.14	0.64	1.76	1.31	1.47	1.77
% Change			37.8%	-0.1%	4.7%	-43.6%	173.3%	-25.4%	12.0%	20.7%
EPS adjusted and fully diluted		0.79	1.09	1.09	1.14	0.64	1.76	1.31	1.47	1.77
% Change			37.8%	-0.1%	4.7%	-43.6%	173.3%	-25.4%	12.0%	20.7%
EPS reported		0.79	1.09	1.09	1.14	0.64	1.76	1.31	1.47	1.77
% Change			37.8%	-0.1%	4.7%	-43.6%	173.3%	-25.4%	12.0%	20.7%
EPS Consensus								1.30	1.41	1.82
Cash flow per share		1.65	1.35	1.33	0.62	1.09	3.13	2.79	2.43	2.73
Book value per share		11.18	9.90	9.93	10.16	9.95	10.17	10.16	10.75	11.54
DPS		0.30	0.55	0.60	0.67	0.40	1.32	0.87	0.98	1.18
Number of shares, YE (m)		19.6	23.0	23.2	23.3	23.3	23.3	23.3	23.3	23.3
Nbr of shares, fully diluted, YE (m)		19.6	23.0	23.2	23.3	23.3	23.3	23.3	23.3	23.3
Share price			100	05.0	400	47.0	47.0			
Latest price / year end		9.0	16.0	25.3	16.8	17.3	17.6	26.1	21.3	21.3
52 week high		9.1	16.1	26.7	28.5	21.7	20.0	28.9	26.1	
52 week low		8.8	7.5	15.9	15.0	14.9	8.7	17.3	21.3	
Average price (Year)		8.9	11.3	22.8	23.1	17.5	15.8	23.1	21.3	21.3
Enterprise value (EURm)										
Market capitalisation		175.1	259.3	527.6	539.0	409.4	369.6	498.3	498.3	498.3
Net financial debt		-23.3	-3.2	-8.9	92.2	122.5	147.1	146.0	134.5	119.1
Pension provisions		14.6	16.7	16.4	17.4	18.3	16.8	16.8	16.8	16.8
IFRS 16 debt	0.0	0.0	0.0	0.0	0.0	26.4	38.1	27.9	27.9	27.9
Market value of minorities		3.1	0.0	0.0	0.0	0.0	0.8	-0.8	-0.8	-0.8
MV of equity affiliates (net of tax)		-18.1	-14.9	-11.7	-13.1	-12.6	-7.0	-7.0	-7.0	-7.0
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Enterprise value		151.4	257.9	523.4	635.5	564.0	565.4	681.2	669.6	654.2
Valuation										
P/E adjusted		11.3	10.4	20.9	20.3	27.3	9.0	16.3	14.5	12.1
P/E adjusted and fully diluted		11.3	10.4	20.9	20.3	27.3	9.0	16.3	14.5	12.1
P/E consensus								16.4	15.1	11.7
P/BV		0.8	1.1	2.3	2.3	1.8	1.6	2.1	2.0	1.8
P/CF		5.4	8.3	17.2	37.4	16.1	5.1	7.7	8.8	7.8
Dividend yield (%)		3.4%	4.9%	2.6%	2.9%	2.3%	8.3%	4.1%	4.6%	5.5%
FCF yield (%)		10.5%	7.8%	3.2%	-1.8%	0.0%	15.7%	10.4%	8.5%	9.8%
T CT yietu (70)		10.5%	1.070	3.270	-1.070	0.070	13.170	10.470	0.570	9.670
ROE (%)			11.2%	11.0%	11.4%	6.4%	17.5%	12.9%	14.0%	15.9%
ROIC (%)			17.7%	19.5%	16.4%	9.5%	18.8%	12.5%	12.1%	13.8%
EV/Sales		0.30	0.51	0.98	1.11	0.90	0.69	0.92	0.86	0.80
EV/EBITDA adj.		3.8	5.3	9.6	10.6	9.4	5.5	9.2	8.4	7.4
EV/EBIT adj.		4.9	6.6	11.8	13.0	13.7	7.1	13.4	11.9	10.1
EV/NOPAT		3.5	7.8	13.6	15.5	18.0	7.9	13.7	14.0	11.9
EV/IC		0.9	1.3	2.7	2.1	1.6	1.4	1.7	1.7	1.6
ROIC/WACC			2.2	2.5	2.1	1.2	2.4	1.6	1.5	1.7
EV/IC over ROIC/WACC			0.6	1.1	1.0	1.3	0.6	1.1	1.1	0.9



## **Income statement**

FY to 31/12 (EUR)	12/14	12/15	12/16	12/17	12/18	12/19	12/20	12/21E	12/22E	12/23E
Sales		498.7	506.4	533.0	573.3	626.2	822.0	736.6	781.1	816.1
Gross profit		120.5	130.0	141.6	154.3	167.0	219.0	186.3	197.6	216.3
EBITDA reported		40.3	48.8	54.6	59.8	59.9	102.4	73.8	80.1	88.7
EBITDA adjusted		40.3	48.8	54.6	59.8	59.9	102.4	73.8	80.1	88.7
Depreciation and amortisation		-9.7	-9.9	-10.2	-11.7	-21.1	-28.4	-28.6	-23.8	-24.0
Goodwill impairment		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other financial result and associates		-6.6	-5.0	-5.9	-5.9	-7.0	-18.2	-4.0	-6.0	-6.0
EBIT reported		24.0	33.9	38.5	42.2	31.8	55.8	41.2	50.3	58.7
EBIT adjusted		30.6	38.9	44.4	49.0	41.3	79.3	50.7	56.3	64.7
Net financial items		-3.0	-0.5	-7.5	-8.8	-9.8	-4.9	-10.6	-10.6	-10.6
Associates		-10.7	-2.0	-0.8	0.1	-0.4	-1.7	0.7	0.7	0.7
Others		-2.3	-1.5	-1.0	-1.8	-1.7	-4.6	0.0	0.0	0.0
Earnings before tax		8.0	29.9	29.2	31.7	19.9	44.6	31.3	40.4	48.8
Tax		7.5	-4.9	-4.0	-5.1	-4.9	-4.3	-0.5	-6.0	-7.2
Net profit from continuing op.		15.5	25.0	25.2	26.6	15.0	40.3	30.8	34.5	41.5
Net profit from disc. activities		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit before minorities		15.5	25.0	25.2	26.6	15.0	40.3	30.8	34.5	41.5
Minorities		0.0	0.0	0.0	0.0	0.0	0.7	-0.2	-0.2	-0.2
Net profit reported		15.5	25.0	25.2	26.6	15.0	41.0	30.6	34.3	41.3
Adjustments		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit adjusted		15.5	25.0	25.2	26.6	15.0	41.0	30.6	34.3	41.3
Sales % Change			1.5%	5.3%	7.6%	9.2%	31.3%	-10.4%	6.0%	4.5%
EBITDA reported % Change			21.1%	11.9%	9.5%	0.2%	71.0%	-27.9%	8.5%	10.7%
EBITDA reported % Change			21.1%	11.9%	9.5%	0.2%	71.0%	-27.9%	8.5%	10.7%
EBIT reported % Change										
EBIT adjusted % Change			41.3%	13.6%	9.6%	-24.6%	75.5%	-26.2%	22.2%	16.5%
			27.1%	14.1%	10.4%	-15.7%	92.0%	-36.1%	11.1%	14.8%
Earnings before tax % Change			273.8%	-2.3%	8.6%	-37.2%	124.1%	-29.8%	29.2%	20.6%
Net profit from cont. op. % Change			61.3%	0.8%	5.6%	-43.6%	168.7%	-23.6%	11.9%	20.5%
Net profit adjusted % Change			61.3%	0.8%	5.6%	-43.6%	173.3%	-25.4%	12.0%	20.7%
Net profit adjusted % Change			61.3%	0.8%	5.6%	-43.6%	173.3%	-25.4%	12.0%	20.7%
Gross profit margin (%)		24.2%	25.7%	26.6%	26.9%	26.7%	26.6%	25.3%	25.3%	26.5%
EBITDA margin (%)		8.1%	9.6%	10.2%	10.4%	9.6%	12.5%	10.0%	10.3%	10.9%
EBIT margin (%)		6.1%	7.7%	8.3%	8.5%	6.6%	9.6%	6.9%	7.2%	7.9%
Net profit margin (%)		3.1%	4.9%	4.7%	4.6%	2.4%	5.0%	4.2%	4.4%	5.1%
Tax rate (%)		40.1%	-15.4%	-13.3%	-16.1%	-24.1%	-9.3%	-1.6%	-15.0%	-15.0%
Payout ratio (%)		38.0%	50.5%	55.1%	58.8%	62.3%	75.2%	66.8%	66.7%	66.6%
EPS reported (EUR)		0.79	1.09	1.09	1.14	0.64	1.76	1.31	1.47	1.77
EPS adjusted (EUR)		0.79	1.09	1.09	1.14	0.64	1.76	1.31	1.47	1.77
EPS adj and fully diluted (EUR)		0.79	1.09	1.09	1.14	0.64	1.76	1.31	1.47	1.77
DPS (EUR)		0.30	0.55	0.60	0.67	0.40	1.32	0.87	0.98	1.18
EPS reported % Change			37.8%	-0.1%	4.7%	-43.6%	173.3%	-25.4%	12.0%	20.7%
EPS adjusted % Change			37.8%	-0.1%	4.7%	-43.6%	173.3%	-25.4%	12.0%	20.7%
EPS adj and fully diluted % Change			37.8%	-0.1%	4.7%	-43.6%	173.3%	-25.4%	12.0%	20.7%
DPS % Change			83.3%	9.1%	11.7%	-40.3%	230.0%	-33.7%	11.9%	20.5%
Consensus Sales (EURm)								736.8	800.0	846.5
Consensus EBIT (EURm)								73.8	82.9	92.3
Consensus EBS (EURm)								51.0	58.3	71.8
Consensus EPS (EUR)								1.30	1.41	1.82



Cash flow statement							Market data	as of: 21 Feb	ruary 2022
FY to 31/12 (EUR)	12/14 12/15	12/16	12/17	12/18	12/19	12/20	12/21E	12/22E	12/23E
Net profit before minorities	15.5	25.0	25.2	26.6	15.0	40.3	30.8	34.5	41.5
Depreciation and amortisation	9.7	9.9	10.2	11.7	21.1	28.7	23.1	23.8	24.0
Goodwill impairment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Change in working capital	8.0	0.8	-6.7	-22.5	-13.3	2.6	21.9	-1.5	-1.8
Others	-0.8	-4.6	2.0	-1.4	2.6	1.4	-10.7	0.0	0.0
Levered post tax CF before capex	32.4	31.1	30.7	14.4	25.4	73.0	65.1	56.7	63.8
% Change		-4.0%	-1.3%	-53.1%	76.4%	187.4%	-10.8%	-12.9%	12.4%
Capex	-14.1	-10.9	-13.6	-24.3	-25.3	-14.9	-13.4	-14.2	-14.8
Free cash flow	18.3	20.2	17.1	-9.9	0.1	58.1	51.8	42.6	49.0
% Change		10.4%	-15.3%	-chg	+chg	58000.0%	-10.9%	-17.8%	15.1%
Acquisitions	0.0	-19.7	-5.5	-65.0	-9.6	-53.0	-20.4	0.0	0.0
Divestments	1.2		1.2	-1.0	0.2	-9.0	0.0	0.0	0.0
Dividend paid	-3.2		-6.6	-10.8	-8.6	-5.9	-30.2	-20.0	-22.4
Share buy back	0.0	0.0	0.0	-10.2	-9.8	-0.1	0.0	0.0	0.0
Capital increases	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Others	-2.2	-6.0	0.0	0.0	-9.7	-12.3	0.1	-10.3	-10.5
Change in net financial debt	-14.1	17.7	-6.2	96.9	37.4	22.2	-1.3	-12.3	-16.1
Change in cash and cash equiv.		63.8	53.3	-104.8	-16.2	115.1	1.1	11.6	15.4
Attributable FCF	18.3	20.2	17.1	-9.9	0.1	58.1	51.8	42.6	49.0
Cash flow per share (EUR)	1.65	1.35	1.33	0.62	1.09	3.13	2.79	2.43	2.73
% Change		-18.0%	-2.1%	-53.5%	76.4%	187.4%	-10.8%	-12.9%	12.4%
FCF per share (EUR)	0.93	0.88	0.74	-0.42	0.00	2.49	2.22	1.82	2.10
% Change		-5.7%	-16.1%	-chg	+chg	57995.4%	-10.9%	-17.8%	15.1%
Capex / Sales (%)	2.8%	2.2%	2.6%	4.2%	4.0%	1.8%	1.8%	1.8%	1.8%
Capex / D&A (%)	145.4%	110.1%	133.3%	207.7%	119.9%	52.5%	46.7%	59.6%	61.6%
Cash flow / Sales (%)	6.5%	6.1%	5.8%	2.5%	4.1%	8.9%	8.8%	7.3%	7.8%
FCF / Sales (%)	3.7%	4.0%	3.2%	-1.7%	0.0%	7.1%	7.0%	5.5%	6.0%
FCF Yield (%)	10.5%	7.8%	3.2%	-1.8%	0.0%	15.7%	10.4%	8.5%	9.8%
Unlevered FCF Yield (%)	13.5%	9.8%	4.9%	0.1%	2.2%	12.4%	9.2%	8.2%	9.4%



## **Balance sheet**

FY to 31/12 (EUR)	12/14	12/15	12/16	12/17	12/18	12/19	12/20	12/21E	12/22E	12/23E
Cash and cash equivalents		97.7	161.5	214.8	110.0	93.8	208.9	210.0	221.5	236.9
Inventories		101.0	105.4	107.3	128.4	126.1	139.1	87.8	91.3	95.4
Accounts receivable		118.4	123.2	128.0	96.1	102.6	110.3	69.6	72.4	75.6
Other current assets		1.1	0.5	0.4	0.7	1.4	23.2	23.2	23.2	23.2
Current assets		318.2	390.6	450.5	335.2	323.9	481.5	390.6	408.4	431.2
Tangible assets		55.9	61.8	63.2	80.7	113.1	121.2	111.3	111.9	113.1
Goodwill		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Intangible assets		78.5	92.1	88.3	158.1	173.1	228.7	249.1	249.2	249.4
Financial assets		18.1	14.9	11.7	13.1	12.6	7.0	7.0	7.0	7.0
Other non-current assets		29.7	31.9	33.4	39.0	41.2	45.9	45.9	45.9	45.9
Non-current assets		182.2	200.7	196.6	290.9	340.0	402.8	413.3	414.0	415.3
Short term debt		25.3	25.2	26.6	33.1	22.8	46.5	46.5	46.5	46.5
Accounts payable		178.4	181.7	187.0	159.1	151.1	189.9	119.9	124.6	130.2
Other short term liabilities		1.8	3.7	4.1	1.4	6.0	26.7	26.7	26.7	26.7
Current liabilities		205.5	210.6	217.7	193.6	179.9	263.1	193.1	197.8	203.4
Long term debt		49.1	133.1	179.3	169.1	193.5	309.5	309.5	309.5	309.5
Pension provisions		14.6	16.7	16.4	17.4	18.3	16.8	16.8	16.8	16.8
IFRS16 Debt	0.0	0.0	0.0	0.0	0.0	26.4	38.1	27.9	27.9	27.9
Other long term provisions		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities		8.8	3.6	3.8	8.8	13.5	20.3	20.3	20.3	20.3
Non-current liabilities		72.5	153.4	199.5	195.3	251.7	384.7	374.5	374.5	374.5
Shareholders' equity		219.3	227.3	229.9	237.2	232.4	237.4	237.3	251.0	269.5
Minority interests		3.1	0.0	0.0	0.0	0.0	-0.8	-0.8	-0.8	-0.8
Total equity		222.4	227.3	229.9	237.2	232.4	236.6	236.5	250.2	268.7
Balance sheet total		500.4	591.3	647.1	626.1	664.0	884.4	804.1	822.6	846.6
% Change			18.2%	9.4%	-3.2%	6.1%	33.2%	-9.1%	2.3%	2.9%
Book value per share (EUR)		11.18	9.90	9.93	10.16	9.95	10.17	10.16	10.75	11.54
% Change			-11.4%	0.3%	2.3%	-2.0%	2.2%	0.0%	5.8%	7.3%
Net financial debt		-23.3	-3.2	-8.9	92.2	122.5	147.1	146.0	134.5	119.1
IFRS16 Debt	0.0	0.0	0.0	0.0	0.0	26.4	38.1	27.9	27.9	27.9
Pension provisions		14.6	16.7	16.4	17.4	18.3	16.8	16.8	16.8	16.8
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net debt		-8.7	13.5	7.5	109.6	167.2	202.0	190.7	179.2	163.8
Net fi. debt (+IFRS16) / EBITDA (x)		-0.6	-0.1	-0.2	1.5	2.5	1.8	2.4	2.0	1.7
Trade working capital		41.0	46.9	48.3	65.4	77.6	59.5	37.6	39.1	40.8
Net working capital		40.3	43.7	44.6	64.7	73.0	56.0	34.1	35.6	37.3
NWC/Sales		8.1%	8.6%	8.4%	11.3%	11.7%	6.8%	4.6%	4.6%	4.6%
Inventories/sales		20.3%	20.8%	20.1%	22.4%	20.1%	16.9%	11.9%	11.7%	11.7%
Invested capital		174.7	197.6	196.1	303.5	359.2	405.9	394.5	396.7	399.7
Net fin. debt / FCF (x)		-1.3	-0.2	-0.5	-9.3	1,225.0	2.5	2.8	3.2	2.4
Gearing (%)		-10.5%	-1.4%	-3.9%	38.9%	52.7%	62.2%	61.7%	53.7%	44.3%
Goodwill / Equity (%)		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

# **Research ratings and important disclosures**

The term "KEPLER CHEUVREUX" shall, unless the context otherwise requires, mean each of KEPLER CHEUVREUX and its affiliates, subsidiaries and related companies (see "Regulators" table below).

The investment recommendation(s) referred to in this report was (were) completed on 21/02/2022 16:22 (GMT) and was first disseminated on 22/02/2022 6:07 (GMT).

Unless otherwise stated, all prices are aligned with the "Market Data date" on the front page of this report.

#### Disclosure checklist - Potential conflict of interests

<b>Company Name</b>	ISIN	Disclosure
Chargeurs	FR0000130692	KEPLER CHEUVREUX and the issuer have agreed that KEPLER CHEUVREUX will produce and disseminate investment
		research on the said issuer as a service to the issuer

#### Organizational and administrative arrangements to avoid and prevent conflicts of interests

KEPLER CHEUVREUX promotes and disseminates independent investment research and have implemented written procedures designed to identify and manage potential conflicts of interest that arise in connection with its research business, which are available upon request. The KEPLER CHEUVREUX research analysts and other staff involved in issuing and disseminating research reports operate independently of KEPLER CHEUVREUX Investment Banking business. Information barriers and procedures are in place between the research analysts and staff involved in securities trading for the account of KEPLER CHEUVREUX or clients to ensure that price sensitive information is handled according to applicable laws and regulations.

It is Kepler Cheuvreux' policy not to disclose the rating to the issuer before publication and dissemination. Nevertheless, this document, in whole or in part, and with the exclusion of ratings, target prices and any other information that could lead to determine its valuation, may have been provided to the issuer prior to publication and dissemination, solely with the aim of verifying factual accuracy.

Please refer to www.keplercheuvreux.com for further information relating to research and conflict of interest management.

#### **Analyst disclosures**

The functional job title of the person(s) responsible for the recommendations contained in this report is Equity/Credit Research Analyst unless otherwise stated on the cover.

Name of the Research Analyst(s): Baptiste de Leudeville

Regulation AC - Analyst Certification: Each Equity/Credit Research Analyst(s) listed on the front-page of this report, principally responsible for the preparation and content of all or any identified portion of this research report hereby certifies that, with respect to each issuer or security or any identified portion of the report with respect to an issuer or security that the equity research analyst covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each Equity/Credit Research Analyst(s) also certifies that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that equity research analyst in this research report.

Each Equity/Credit Research Analyst certifies that he is acting independently and impartially from KEPLER CHEUVREUX shareholders, directors and is not affected by any current or potential conflict of interest that may arise from any KEPLER CHEUVREUX activities.

**Analyst Compensation:** The research analyst(s) primarily responsible for the preparation of the content of the research report attest that no part of the analyst's(s') compensation was, is or will be, directly or indirectly, related to the specific recommendations expressed by the research analyst(s) in the research report. The research analyst's(s') compensation is, however, determined by the overall economic performance of KEPLER CHEUVREUX.

Registration of non-US Analysts: Unless otherwise noted, the non-US analysts listed on the front of this report are employees of KEPLER CHEUVREUX, which is a non-US affiliate and parent company of Kepler Capital Markets, Inc. a SEC registered and FINRA member broker-dealer. Equity/Credit Research Analysts employed by KEPLER CHEUVREUX, are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of Kepler Capital Markets, Inc. and may not be subject to NASD Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

#### **Research ratings**

Kepler Cheuvreux rating split as of 22 February 2022		_
Rating Breakdown	A	В
Buy	62%	70%
Hold	31%	21%
Reduce	4%	0%
Not Rated/Under Review/Accept Offer	3%	9%
Total	100%	100%

Source: Kepler Cheuvreux

A: % of all research recommendations

B: % of issuers to which material services of investment firms are supplied

#### 12 months rating history

The below table shows the history of recommendations and target prices changes issued by KEPLER CHEUVREUX research department (Equity and Credit) over a 12 months period.

Company Name	Date	Business Line	Rating	Target Price	Closing Price
Chargeurs (EUR)	26/05/2021 05:10	Equity Research	Buy	30.00	20.88

Credit research does not issue target prices. Left intentionally blank.

Please refer to the following link <a href="https://research.keplercheuvreux.com/disclosure/stock/">https://research.keplercheuvreux.com/disclosure/stock/</a> for a full list of investment recommendations issued over the last 12 months by the author(s) and contributor(s) of this report on any financial instruments.

#### **Equity research**

#### Rating system

KEPLER CHEUVREUX equity research ratings and target prices are issued in absolute terms, not relative to any given benchmark. A rating on a stock is set after assessing the twelve months expected upside or downside of the stock derived from the analyst's fair value (target price) and in the light of the risk profile of the company. Ratings are defined as follows:

Buy: The minimum expected upside is 10% over next 12 months (the minimum required upside could be higher in light of the company's risk profile).

Hold: The expected upside is below 10% (the expected upside could be higher in light of the company's risk profile).

Reduce: There is an expected downside.

Accept offer: In the context of a total or partial take-over bid, squeeze-out or similar share purchase proposals, the offer price is considered to be fairly valuing the shares.

Reject offer: In the context of a total or partial take-over bid, squeeze-out or similar share purchase proposals, the offered price is considered to be undervaluing the shares.

**Under review:** An event occurred with an expected significant impact on our target price and we cannot issue a recommendation before having processed that new information and/or without a new share price reference.

Not rated: The stock is not covered.

 $\textbf{Restricted} : A \ recommendation, target \ price \ and/or \ financial \ forecast \ is \ not \ disclosed \ further \ to \ compliance \ and/or \ other \ regulatory \ considerations.$ 

Due to share prices volatility, ratings and target prices may occasionally and temporarily be inconsistent with the above definition.

#### Valuation methodology and risks

Unless otherwise stated in this report, target prices and investment recommendations are determined based on fundamental research methodologies and relies on commonly used valuation methodologies such as Discounted Cash Flow (DCF), valuation multiples comparison with history and peers, Dividend Discount Model (DDM).

Valuation methodologies and models can be highly dependent on macroeconomic factors (such as the price of commodities, exchange rates and interest rates) as well as other external factors including taxation, regulation and geopolitical changes (such as tax policy changes, strikes or war). In addition, investors' confidence and market sentiment can affect the valuation of companies. The valuation is also based on expectations that might change rapidly and without notice, depending on developments specific to individual industries. Whichever valuation method is used there is a significant risk that the target price will not be achieved within the expected timeframe.

Unless otherwise stated, models used are proprietary. Additional information about the proprietary models used in this report is accessible on request.

KEPLER CHEUVREUX' equity research policy is to update research rating when it deems appropriate in the light of new findings, markets development and any relevant information that can impact the analyst's view and opinion.

#### **Regulators**

Location	Regulator	Abbreviation
KEPLER CHEUVREUX S.A - France	Autorité des Marchés Financiers	AMF
KEPLER CHEUVREUX, Sucursal en España	Comisión Nacional del Mercado de Valores	CNMV
KEPLER CHEUVREUX, Frankfurt branch	Bundesanstalt für Finanzdienstleistungsaufsicht	BaFin
KEPLER CHEUVREUX, Milan branch	Commissione Nazionale per le Società e la Borsa	CONSOB
KEPLER CHEUVREUX, Amsterdam branch	Autoriteit Financiële Markten	AFM
Kepler Capital Markets SA - Switzerland, Zurich branch	Swiss Financial Market Supervisory Authority	FINMA
Kepler Capital Markets, Inc.	Financial Industry Regulatory Authority	FINRA
KEPLER CHEUVREUX, London branch	Financial Conduct Authority	FCA
KEPLER CHEUVREUX, Vienna branch	Austrian Financial Services Authority	FMA
KEPLER CHEUVREUX, Stockholm Branch	Finansinspektionen	FI
KEPLER CHEUVREUX Oslo Branch	Finanstilsynet	NFSA
KEPLER CHEUVREUX, Bruxelles Branch	Autorité des Services et Marchés Financiers	FSMA

KEPLER CHEUVREUX is authorised and regulated by both Autorité de Contrôle Prudentiel and Autorité des Marchés Financiers.

# **Legal and disclosure information**

#### Other disclosures

This product is not for distribution to retail clients.

MIFID 2 WARNING: We remind you that pursuant to MiFID 2, it is your responsibility, as a recipient of this research document, to determine whether or not your firm is impacted by the provisions of the Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments ("MiFID 2") regarding the unbundling of research and execution (the "MiFID 2 Research Rules"). For any request on the provision of research documents, please send an email to crystal.team@keplercheuvreux.com.

The information contained in this publication was obtained from various publicly available sources believed to be reliable, but has not been independently verified by KEPLER CHEUVREUX. KEPLER CHEUVREUX does not warrant the completeness or accuracy of such information and does not accept any liability with respect to the accuracy or completeness of such information, except to the extent required by applicable law.

This publication is a brief summary and does not purport to contain all available information on the subjects covered. Further information may be available on request.

This publication is for information purposes only and shall not be construed as an offer or solicitation for the subscription or purchase or sale of any securities, or as an invitation, inducement or intermediation for the sale, subscription or purchase of any securities, or for engaging in any other transaction.

Any opinions, projections, forecasts or estimates in this report are those of the author only, who has acted with a high degree of expertise. They reflect only the current views of the author at the date of this report and are subject to change without notice. KEPLER CHEUVREUX has no obligation to update, modify or amend this publication or to otherwise notify a reader or recipient of this publication in the event that any matter, opinion, projection, forecast or estimate contained herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. The analysis, opinions, projections, forecasts and estimates expressed in this report were in no way affected or influenced by the issuer. The author of this publication benefits financially from the overall success of KEPLER CHE UVREUX.

The investments referred to in this publication may not be suitable for all recipients. Recipients are urged to base their investment decisions upon their own appropriate investigations that they deem necessary. Any loss or other consequence arising from the use of the material contained in this publication shall be the sole and exclusive responsibility of the investor and KEPLER CHEUVREUX accepts no liability for any such loss or consequence. In the event of any doubt about any investment, recipients should contact their own investment, legal and/or tax advisers to seek advice regarding the appropriateness of investing. Some of the investments mentioned in this publication may not be readily liquid investments. Consequently it may be difficult to sell or realise such investments. The past is not necessarily a guide to future performance of an investment. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in this publication may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may cause losses. International investing includes risks related to political and economic uncertainties of foreign countries, as well as currency risk.

To the extent permitted by applicable law, no liability whatsoever is accepted for any direct or consequential loss, damages, costs or prejudices whatsoever arising from the use of this publication or its contents.

#### **Country and region disclosures**

**United Kingdom**: This document is for persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restriction in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Articles 19(5) (Investment professionals) and 49(2) (High net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Any investment to which this document relates is available only to such persons, and other classes of person should not rely on this document.

**United States**: This communication is only intended for, and will only be distributed to, persons residing in any jurisdictions where such distribution or availability would not be contrary to local law or regulation. This communication must not be acted upon or relied on by persons in any jurisdiction other than in accordance with local law or regulation and where such person is an investment professional with the requisite sophistication to understand an investment in such securities of the type communicated and assume the risks associated therewith.

This communication is confidential and is intended solely for the addressee. It is not to be forwarded to any other person or copied without the permission of the sender. This communication is provided for information only. It is not a personal recommendation or an offer to sell or a solicitation to buy the securities mentioned. Investors should obtain independent professional advice before making an investment.

Notice to U.S. Investors: This material is not for distribution in the United States, except to "major US institutional investors" as defined in SEC Rule 15a-6 ("Rule 15a-6"). KEPLER CHEUVREUX has entered into a 15a-6 Agreement with Kepler Capital Markets, Inc. ("KCM, Inc.") which enables this report to be furnished to certain U.S. recipients in reliance on Rule 15a-6 through KCM. Inc.

Each U.S. recipient of this report represents and agrees, by virtue of its acceptance thereof, that it is a "major U.S. institutional investor" (as such term is defined in Rule 15a-6) and that it understands the risks involved in executing transactions in such securities. Any U.S. recipient of this report that wishes to discuss or receive additional information regarding any security or issuer mentioned herein, or engage in any transaction to purchase or sell or solicit or offer the purchase or sale of such securities, should contact a registered representative of KCM, Inc.

KCM, Inc. is a broker-dealer registered with the Securities and Exchange Commission ("SEC") under the U.S. Securities Exchange Act of 1934, as amended, Member of the Financial Industry Regulatory Authority ("FINRA") and Member of the Securities Investor Protection Corporation ("SIPC"). Pursuant to SEC Rule 15a-6, you must contact a Registered Representative of KCM, Inc. if you are seeking to execute a transaction in the securities discussed in this report. You can reach KCM, Inc. at Tower 49, 12 East 49th Street, Floor 36, New York, NY 10017, Compliance Department (212) 710-7625; Operations Department (212) 710-7606; Trading Desk (212) 710-7602. Further information is also available at www.keplercheuvreux.com. You may obtain information about SIPC, including the SIPC brochure, by contacting SIPC directly at 202-371-8300; website: http://www.sipc.org/.

KCM, Inc. is a wholly owned subsidiary of KEPLER CHEUVREUX. KEPLER CHEUVREUX, registered on the Paris Register of Companies with the number 413 064 841 (1997 B 10253), whose registered office is located at 112 avenue Kléber, 75016 Paris, is authorised and regulated by both Autorité de Contrôle Prudentiel (ACP) and Autorité des Marchés Financiers (AMF).

Nothing herein excludes or restricts any duty or liability to a customer that KCM, Inc. may have under applicable law. Investment products provided by or through KCM, Inc. are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution, may lose value and are not guaranteed by the entity that published the research as disclosed on the front page and are not guaranteed by KCM, Inc.

Investing in non-U.S. Securities may entail certain risks. The securities referred to in this report and non-U.S. issuers may not be registered under the U.S. Securities Act of 1933, as amended, and the issuer of such securities may not be subject to U.S. reporting and/or other requirements. Rule 144A securities may be offered or sold only to persons in the U.S. who are Qualified Institutional Buyers within the meaning of Rule 144A under the Securities Act. The information available about non-U.S. companies may be limited, and non-U.S. companies are generally not subject to the same uniform auditing and reporting standards as U.S. companies. Securities of some non-U.S. companies may not be as

liquid as securities of comparable U.S. companies. Securities discussed herein may be rated below investment grade and should therefore only be considered for inclusion in accounts qualified for speculative investment.

Analysts employed by KEPLER CHEUVREUX SA, a non-U.S. broker-dealer, are not required to take the FINRA analyst exam. The information contained in this report is intended solely for certain "major U.S. institutional investors" and may not be used or relied upon by any other person for any purpose. Such information is provided for informational purposes only and does not constitute a solicitation to buy or an offer to sell any securities under the Securities Act of 1933, as amended, or under any other U.S. federal or state securities laws, rules or regulations. The investment opportunities discussed in this report may be unsuitable for certain investors depending on their specific investment objectives, risk tolerance and financial position.

In jurisdictions where KCM, Inc. is not registered or licensed to trade in securities, or other financial products, transactions may be executed only in accordance with applicable law and legislation, which may vary from jurisdiction to jurisdiction and which may require that a transaction be made in accordance with applicable exemptions from registration or licensing requirements.

The information in this publication is based on sources believed to be reliable, but KCM, Inc. does not make any representation with respect to its completeness or accuracy. All opinions expressed herein reflect the author's judgment at the original time of publication, without regard to the date on which you may receive such information, and are subject to change without notice.

KCM, Inc. and/or its affiliates may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. These publications reflect the different assumptions, views and analytical methods of the analysts who prepared them. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is provided in relation to future performance.

KCM, Inc. and any company affiliated with it may, with respect to any securities discussed herein: (a) take a long or short position and buy or sell such securities; (b) act as investment and/or commercial bankers for issuers of such securities; (c) act as market makers for such securities; (d) serve on the board of any issuer of such securities; and (e) act as paid consultant or advisor to any issuer. The information contained herein may include forward-looking statements within the meaning of U.S. federal securities laws that are subject to risks and uncertainties. Factors that could cause a company's actual results and financial condition to differ from expectations include, without limitation: political uncertainty, changes in general economic conditions that adversely affect the level of demand for the company's products or services, changes in foreign exchange markets, changes in international and domestic financial markets and in the competitive environment, and other factors relating to the foregoing. All forward-looking statements contained in this report are qualified in their entirety by this cautionary statement.

France: This publication is issued and distributed in accordance with legal or regulatory requirements relating to independent investment research, as defined under Article 36 of the EU delegated regulation n°565/2017.

**Germany**: This report must not be distributed to persons who are retail clients in the meaning of Sec. 31a para. 3 of the German Securities Trading Act (Wertpapierhandelsgesetz – "WpHG"). This report may be amended, supplemented or updated in such manner and as frequently as the author deems.

Italy: This document is issued by KEPLER CHEUVREUX Milan branch, authorised in France by the Autorité des Marchés Financiers (AMF) and the Autorité de Contrôle Prudentiel (ACP) and registered in Italy by the Commissione Nazionale per le Società e la Borsa (CONSOB) and is distributed by KEPLER CHEUVREUX. This document is for Eligible Counterparties or Professional Clients only as defined by the CONSOB Regulation 16190/2007 (art. 26 and art. 58). Other classes of persons should not rely on this document. Reports on issuers of financial instruments listed by Article 180, paragraph 1, letter a) of the Italian Consolidated Act on Financial Services (Legislative Decree No. 58 of 24/2/1998, as amended from time to time) must comply with the requirements envisaged by articles 69 to 69-novies of CONSOB Regulation 11971/1999. According to these provisions KEPLER CHEUVREUX warns on the significant interests of KEPLER CHEUVREUX indicated in Annex 1 hereof, confirms that there are not significant financial interests of KEPLER CHEUVREUX in relation to the securities object of this report as well as other circumstance or relationship with the issuer of the securities object of this report (including but not conflict of interest, significant shareholdings held in or by the issuer and other significant interests held by KEPLER CHEUVREUX or other entities controlling or subject to control by KEPLER CHEUVREUX in relation to the issuer which may affect the impartiality of this document]. Equities discussed herein are covered on a continuous basis with regular reports at results release. Reports are released on the date shown on cover and distributed via print and email. KEPLER CHEUVREUX branch di Milano analysts is not affiliated with any professional groups or organisations. All estimates are by KEPLER CHEUVREUX unless otherwise stated.

Spain: This document is only intended for persons who are Eligible Counterparties or Professional Clients within the meaning of Article 78bis and Article 78ter of the Spanish Securities Market Act. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This report has been issued by KEPLER CHEUVREUX Sucursal en España registered in Spain by the Comisión Nacional del Mercado de Valores (CNMV) in the foreign investments firms registry and it has been distributed in Spain by it or by KEPLER CHEUVREUX authorised and regulated by both Autorité de Contrôle Prudentiel and Autorité des Marchés Financiers. There is no obligation to either register or file any report or any supplemental documentation or information with the CNMV. In accordance with the Spanish Securities Market Law (Ley del Mercado de Valores), there is no need for the CNMV to verify, authorise or carry out a compliance review of this document or related documentation, and no information needs to be provided.

**Switzerland**: This publication is intended to be distributed to professional investors in circumstances such that there is no public offer. This publication does not constitute a prospectus within the meaning of Articles 652a and 1156 of the Swiss Code of Obligations.

Canada: The information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. In Canada, the information contained herein is intended solely for distribution to Permitted Clients (as such term is defined in National Instrument 31-103) with whom Kepler Capital Markets, inc. deals pursuant to the international dealer exemption. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities may not be conducted through Kepler Capital Markets, inc. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein.

Other countries: Laws and regulations of other countries may also restrict the distribution of this report. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly.

None of the material, nor its content may be altered in anyway, transmitted to, copied or distributed to any other party, in whole or in part, unless otherwise agreed with KEPLER CHEUVREUX in writing.

Copyright © KEPLER CHEUVREUX. All rights reserved.



# Local insight, European scale.





### Europe



#### Amsterdam

Kepler Cheuvreux Benelux Johannes Vermeerstraat 9 1071 DK Amsterdam +31 20 563 2365



Kepler Cheuvreux Belgium **Rogier Tower** Place Rogier 11 1210 Brussels

+32 11 491460



Kepler Cheuvreux Germany Taunusanlage 19 60325 Frankfurt

+49 69 756 960

#### Geneva

Kepler Cheuvreux SA Route de Crassier 11 1262 Eysins Switzerland

+41 22361 5151

#### London

Kepler Cheuvreux UK 5th Floor 95 Gresham Street London EC2V 7NA

+44 20 7621 5100



Kepler Cheuvreux Espana Paseo de la Castellana, 52 28046 Madrid

+34 914 36 5100

### Milan

Kepler Cheuvreux Italia Via C. Cornaggia 10 20123 Milan

+39 02 8550 7201



## Oslo

Kepler Cheuvreux Norway Filipstad Brygge 1 Pb. 1671 Vika 0120 Oslo

+47 23 13 9080

### Paris

Kepler Cheuvreux France 112 Avenue Kleber 75016 Paris

+33 1 53 65 35 00

#### Stockholm

Kepler Cheuvreux Sweden Malmskillnadsgatan 23 11157 Stockholm

+46 8 723 51 00



### Vienna

Kepler Cheuvreux Austria Schottenring 16/2 1010 Vienna

+43 1 537 124 147

Kepler Cheuvreux Switzerland Stadelhoferstrasse 22 8001 Zurich

+41 43 333 66 66

### **North America**



#### New York

Kepler Capital Markets, Inc. Tower 49 12 East 49th Street, Floor 36 10017 New York, NY USA

+1 212 710 7600

